Interferon alpha 2A in the treatment of chronic myelogenous leukemia in chronic phase. Results of the Spanish Group.

@article{FernndezRaada1993InterferonA2,
  title={Interferon alpha 2A in the treatment of chronic myelogenous leukemia in chronic phase. Results of the Spanish Group.},
  author={J M Fern{\'a}ndez-Ra{\~n}ada and Esperanza Lavilla and Jes{\'u}s Odriozola and Jos{\'e} Garc{\'i}a-Lara{\~n}a and Miguel Lozano and R Parody and M P Giraldo and F{\'e}lix Carbonell and Maria Teresa Ferr{\`o} and Juan Luis Steegmann},
  journal={Leukemia & lymphoma},
  year={1993},
  volume={11 Suppl 1},
  pages={175-9}
}
Fifty-one patients with CML in chronic phase, less than two years after diagnosis, were included in one multicentric study aiming to assess the therapeutic value of interferon alpha 2a (IFN alpha 2a) in this setting. The therapeutic scheme was biphasic: The patients were first treated with hydroxyurea, and afterwards only received IFN alpha 2a, at a planned dose of 5MU/m2/day, s.c. Thirty-eight patients (81%) achieved an hematologic response, which was complete in 57% of the total group. The… CONTINUE READING